Molecular mechanisms of coronary microembolization-induced MINOCA.

IF 9.2 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Jasper Iske,Henriette Thau,Joshua M Mesfin,Christien M Beez,Petra Wolint,Jonas Hildinger,Nicolas Musigk,Timo Z Nazari-Shafti,Adam Penkalla,Volkmar Falk,Bettina Heidecker,Bertil Lindahl,Maximilian Y Emmert,Nikola Cesarovic
{"title":"Molecular mechanisms of coronary microembolization-induced MINOCA.","authors":"Jasper Iske,Henriette Thau,Joshua M Mesfin,Christien M Beez,Petra Wolint,Jonas Hildinger,Nicolas Musigk,Timo Z Nazari-Shafti,Adam Penkalla,Volkmar Falk,Bettina Heidecker,Bertil Lindahl,Maximilian Y Emmert,Nikola Cesarovic","doi":"10.1007/s00395-026-01189-2","DOIUrl":null,"url":null,"abstract":"Compared to classic myocardial infarction (cMI), myocardial infarction with non-obstructive coronary arteries (MINOCA) is characterized by symptoms consistent with acute coronary syndrome, but without demonstrable coronary obstruction. Therefore, its diagnosis remains challenging and often relies on cardiac magnetic resonance imaging (MRI), which is usually performed only days after the index event, leading to delayed diagnosis and initiation of therapy. Coronary microembolization (CME) has been described as one of the major pathologies underlying MINOCA. However, the molecular mechanisms of CME remain poorly understood, resulting in a lack of rapid diagnostic tools and specific therapy approaches. In this review, we describe the molecular underpinnings of CME-derived MINOCA: an inflammatory environment inducing significant cellular damage that is conserved between cMI and MINOCA. While we note that some of these inflammatory and cellular death pathways are shared with cMI, we dissect mechanistic distinctions in CME-derived MINOCA such as dysregulated immune responses and higher miRNA activity. Most importantly, as molecular treatments for MI are currently in late-stage clinical trials, we can thus differentiate which therapeutics may work better for MINOCA. Thus, these findings can be used as a roadmap for diagnostic biomarkers and targeted therapeutic approaches for MINOCA.","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"365 1","pages":""},"PeriodicalIF":9.2000,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00395-026-01189-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Compared to classic myocardial infarction (cMI), myocardial infarction with non-obstructive coronary arteries (MINOCA) is characterized by symptoms consistent with acute coronary syndrome, but without demonstrable coronary obstruction. Therefore, its diagnosis remains challenging and often relies on cardiac magnetic resonance imaging (MRI), which is usually performed only days after the index event, leading to delayed diagnosis and initiation of therapy. Coronary microembolization (CME) has been described as one of the major pathologies underlying MINOCA. However, the molecular mechanisms of CME remain poorly understood, resulting in a lack of rapid diagnostic tools and specific therapy approaches. In this review, we describe the molecular underpinnings of CME-derived MINOCA: an inflammatory environment inducing significant cellular damage that is conserved between cMI and MINOCA. While we note that some of these inflammatory and cellular death pathways are shared with cMI, we dissect mechanistic distinctions in CME-derived MINOCA such as dysregulated immune responses and higher miRNA activity. Most importantly, as molecular treatments for MI are currently in late-stage clinical trials, we can thus differentiate which therapeutics may work better for MINOCA. Thus, these findings can be used as a roadmap for diagnostic biomarkers and targeted therapeutic approaches for MINOCA.
冠状动脉微栓塞诱导MINOCA的分子机制。
与经典心肌梗死(cMI)相比,非阻塞性冠状动脉心肌梗死(MINOCA)的特征是症状与急性冠状动脉综合征一致,但没有明显的冠状动脉阻塞。因此,其诊断仍然具有挑战性,通常依赖于心脏磁共振成像(MRI),这通常在指数事件发生后几天进行,导致诊断和开始治疗延迟。冠状动脉微栓塞(CME)已被描述为MINOCA的主要病理之一。然而,CME的分子机制仍然知之甚少,导致缺乏快速诊断工具和特异性治疗方法。在这篇综述中,我们描述了cme衍生的MINOCA的分子基础:炎症环境诱导cMI和MINOCA之间保守的显著细胞损伤。虽然我们注意到这些炎症和细胞死亡途径中的一些与cMI相同,但我们分析了cme衍生的MINOCA的机制差异,如免疫反应失调和更高的miRNA活性。最重要的是,由于心肌梗死的分子治疗目前处于后期临床试验阶段,因此我们可以区分哪种治疗方法可能对MINOCA更有效。因此,这些发现可以作为MINOCA诊断生物标志物和靶向治疗方法的路线图。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Basic Research in Cardiology
Basic Research in Cardiology 医学-心血管系统
CiteScore
16.30
自引率
5.30%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Basic Research in Cardiology is an international journal for cardiovascular research. It provides a forum for original and review articles related to experimental cardiology that meet its stringent scientific standards. Basic Research in Cardiology regularly receives articles from the fields of - Molecular and Cellular Biology - Biochemistry - Biophysics - Pharmacology - Physiology and Pathology - Clinical Cardiology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书